S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NYSE:STE

STERIS Stock Forecast, Price & News

$227.31
-0.69 (-0.30%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$226.75
$230.27
50-Day Range
$204.28
$236.73
52-Week Range
$170.36
$237.35
Volume
232,647 shs
Average Volume
581,578 shs
Market Capitalization
$22.74 billion
P/E Ratio
81.18
Dividend Yield
0.75%
Beta
0.6
30 days | 90 days | 365 days | Advanced Chart
Receive STE News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.


STERIS logo

About STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers portfolio of infection prevention, procedural, and gastrointestinal solutions. The Healthcare Specialty Services segment delivers solutions and managed services including hospital sterilization services and instrument, and scope repairs to acute care hospitals and other healthcare settings. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capitalequipment. The Applied Sterilization Technologies segment involves in contract sterilization and testing services for medical device and pharmaceutical manufacturer. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Headlines

STERIS (NYSE:STE) Hits New 52-Week High at $237.36
November 16, 2021 |  americanbankingnews.com
STERIS (NYSE:STE) Price Target Raised to $256.00 at KeyCorp
November 4, 2021 |  americanbankingnews.com
STERIS (NYSE:STE) PT Raised to $270.00
November 4, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
85915210
Employees
13,000
Year Founded
1987

Sales & Book Value

Annual Sales
$3.11 billion
Cash Flow
$8.62 per share
Book Value
$65.43 per share

Profitability

Net Income
$397.40 million
Pretax Margin
8.73%

Debt

Price-To-Earnings

Miscellaneous

Free Float
98,883,000
Market Cap
$22.74 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Ex-Dividend
11/22/2021
Today
11/27/2021
Dividend Payable
12/17/2021
Next Earnings (Estimated)
2/01/2022
Fiscal Year End
3/31/2022

Social Links


MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

107th out of 1,392 stocks

Surgical Appliances & Supplies Industry

3rd out of 27 stocks

Analyst Opinion: 1.4Community Rank: 4.0Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












STERIS (NYSE:STE) Frequently Asked Questions

Is STERIS a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STERIS stock.
View analyst ratings for STERIS
or view top-rated stocks.

How has STERIS's stock price been impacted by COVID-19?

STERIS's stock was trading at $145.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STE shares have increased by 56.5% and is now trading at $227.31.
View which stocks have been most impacted by COVID-19
.

When is STERIS's next earnings date?

STERIS is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for STERIS
.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) released its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported $1.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.82 by $0.17. The medical equipment provider had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.16 billion. STERIS had a trailing twelve-month return on equity of 12.44% and a net margin of 6.50%. During the same period in the prior year, the firm earned $1.48 earnings per share.
View STERIS's earnings history
.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS declared a quarterly dividend on Thursday, October 28th. Investors of record on Tuesday, November 23rd will be given a dividend of $0.43 per share on Friday, December 17th. This represents a $1.72 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date of this dividend is Monday, November 22nd.
View STERIS's dividend history
.

Is STERIS a good dividend stock?

STERIS pays an annual dividend of $1.72 per share and currently has a dividend yield of 0.75%. STERIS has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of STERIS is 61.43%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STERIS will have a dividend payout ratio of 19.84% next year. This indicates that STERIS will be able to sustain or increase its dividend.
View STERIS's dividend history.

What guidance has STERIS issued on next quarter's earnings?

STERIS issued an update on its FY 2022 earnings guidance on Tuesday, November, 9th. The company provided earnings per share (EPS) guidance of $7.600-$7.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.720. The company issued revenue guidance of -.

What price target have analysts set for STE?

6 brokers have issued 1-year price targets for STERIS's stock. Their forecasts range from $233.00 to $270.00. On average, they anticipate STERIS's stock price to reach $248.80 in the next year. This suggests a possible upside of 9.5% from the stock's current price.
View analysts' price targets for STERIS
or view top-rated stocks among Wall Street analysts.

Who are STERIS's key executives?

STERIS's management team includes the following people:
  • Daniel A. Carestio, President, Chief Executive Officer & Director
  • Michael Joseph Tokich, Chief Financial Officer & Senior Vice President
  • Kathleen Lynn Bardwell, Chief Compliance Officer & Senior Vice President
  • John Adam Zangerle, Secretary, Senior Vice President & General Counsel
  • Renato G. Tamaro, Treasurer & Vice President

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS CEO Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among STERIS's employees.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

What is STERIS's stock symbol?

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Who are STERIS's major shareholders?

STERIS's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.69%), WCM Investment Management LLC (6.83%), Massachusetts Financial Services Co. MA (4.30%), Generation Investment Management LLP (3.13%), Janus Henderson Group PLC (2.89%) and Geode Capital Management LLC (1.85%). Company insiders that own STERIS stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS
.

Which institutional investors are selling STERIS stock?

STE stock was sold by a variety of institutional investors in the last quarter, including Alta Capital Management LLC, Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., Retirement Systems of Alabama, Morgan Stanley, Schroder Investment Management Group, Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Cynthia L Feldmann, David B Lewis, Jacqueline B Kosecoff, Julia Madsen, Michael J Tokich, and Renato Tamaro.
View insider buying and selling activity for STERIS
or view top insider-selling stocks.

Which institutional investors are buying STERIS stock?

STE stock was acquired by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Principal Financial Group Inc., Alliancebernstein L.P., Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., Strs Ohio, Polar Capital Holdings Plc, and Geode Capital Management LLC.
View insider buying and selling activity for STERIS
or or view top insider-buying stocks.

How do I buy shares of STERIS?

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STERIS's stock price today?

One share of STE stock can currently be purchased for approximately $227.31.

How much money does STERIS make?

STERIS has a market capitalization of $22.74 billion and generates $3.11 billion in revenue each year. The medical equipment provider earns $397.40 million in net income (profit) each year or $2.80 on an earnings per share basis.

How many employees does STERIS have?

STERIS employs 13,000 workers across the globe.

When was STERIS founded?

STERIS was founded in 1987.

What is STERIS's official website?

The official website for STERIS is www.steris.com.

Where are STERIS's headquarters?

How can I contact STERIS?

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at (531) 232-2000, via email at [email protected], or via fax at 440-639-4457.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.